Skip to main content

Biomarker Consortia: Disease Stratification and Progression

Biomarker Consortia: Disease Stratification and Progression

Funding Agency
Target ALS
Funding Type
Wednesday, May 29, 2024

As new therapeutics have begun moving the needle for ALS patients, tracking disease progression and monitoring the effects of drug treatment have become even more important. Biomarkers are needed to stratify patient populations, understand response to therapeutics, and quantify disease progression. We are soliciting proposals from collaborative groups focused on the discovery and development of novel disease progression and stratification biomarkers using any modality.

This call is focused on bringing investigators together to work collaboratively on ALS biology with the aim of identifying novel ALS disease progression biomarkers. Only collaborative projects will be considered.

The total budget for a collaborative project cannot exceed a maximum of $500,000 per year.